Last reviewed · How we verify
NCT05567692: DESCENDANCE
Subjects With T2D or at Risk of T2D Cohort Follow-up
trial testing OGTT in Diabetes Mellitus, Type 2 in 837 participants. Participants enrolled and being followed up; not accepting new ones.
1 October 2032
Quick facts
| Lead sponsor | Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 837 |
| Start date | 10 February 2023 |
| Primary completion | 1 October 2032 |
| Estimated completion | 1 October 2032 |
| Sites | 1 location across France |
Drugs / interventions tested
- OGTT — full drug profile →
- HbA1c
- Questionnaire
Conditions studied
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Sponsor
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Who can join
18 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this study is to prospectively follow the subjects included in "Descendance" cohort and to describe the occurrence of type 2 diabetes in non-diabetic subjects, which will allow us to iteratively update the "Descendance" Type 2 Diabetes risk prediction model.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05567692
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of OGTT
Trials testing the same drug.
- NCT06657209 — Normal-weight Diabetes: Adipocyte-directed Therapy with Pioglitazone or Tirzepatide · Phase 4 · not yet recruiting
- NCT06141291 — Bed Rest Study SBI 2023 · NA · completed
- NCT05377502 — Performance and Patient Acceptance of a Commercially Available Beverage as Compared to an Oral Glucose Solution for Oral · unknown
- NCT02653027 — Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del · NA · withdrawn
- NCT02598791 — GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake · NA · completed
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
- NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
Other Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète trials
Trials by the same sponsor.
- NCT06896045 — Multicenter Study Evaluating the Relationship Between Perceived Daily Stress Level and Glycemic Level in Subjects With T · NA · recruiting
- NCT04725591 — Diabeloop for Teens · NA · completed
- NCT06365255 — National Epidemiological Study of the Possible Impact of Stress on Glycaemic Control in Patients With Type 1 Diabetes · completed
- NCT04537520 — Interventional Clinical Trial Comparing Kerecis Omega3 Wound Versus SOC in Diabetic Foot Wounds · NA · completed
- NCT04190277 — Safety Assessment of DBLUS System in Adolescent and Adult Patients With Type 1 Diabetes and Assessment of Its Clinical E · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05567692 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
- Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05567692.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing